JP2005518788A - 骨形成タンパク質(bmp)、bmpレセプターおよびbmp結合タンパク質ならびに緑内障の診断および処置におけるそれらの使用 - Google Patents
骨形成タンパク質(bmp)、bmpレセプターおよびbmp結合タンパク質ならびに緑内障の診断および処置におけるそれらの使用 Download PDFInfo
- Publication number
- JP2005518788A JP2005518788A JP2003556021A JP2003556021A JP2005518788A JP 2005518788 A JP2005518788 A JP 2005518788A JP 2003556021 A JP2003556021 A JP 2003556021A JP 2003556021 A JP2003556021 A JP 2003556021A JP 2005518788 A JP2005518788 A JP 2005518788A
- Authority
- JP
- Japan
- Prior art keywords
- bmp
- seq
- glaucoma
- sequence
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
Abstract
Description
本発明は、緑内障および関連障害の診断および処置のための方法および試薬を開示する。
「緑内障」は、消耗性の眼の疾患の一群であり、米国および他の先進国において回復不能の失明の主要原因である。緑内障のもっとも一般的な形態である原発性開放隅角緑内障(「POAG」)は、虹彩と角膜との間の空間(例えば、「角」)の閉鎖無しに、房水が眼を離れる正常な能力の閉塞を起こす、小柱網の変性によって特徴づけられる(Vaughan,D.ら、(1992))。この疾患におけるこのような閉塞の特徴は、眼内圧力(「IOP」)上昇であり、もし適切にかつ適時な様式で処置されなければ、進行性の視力喪失および失明を起こす。この疾患は、40歳を越える全ての成人のうち0.4%と3.3%との間の人々に影響を及ぼすことが推測される(Leske,M.C.ら、(1986);Bengtsson,B.(1989);Strong,N.P.(1992))。さらに、この疾患の有病率は、年齢とともに増加して、75歳以上では6%を超える(Strong,N.P.、(1992))。
本発明は、先行技術のこれらおよび他の欠点を、緑内障の初期診断のための方法およびキット、緑内障の処置のための方法およびキット、ならびに緑内障の処置において有用な化合物の同定のための方法およびキットを提供することによって克服する。
a)緑内障を有すると疑われる患者から組織サンプルまたは体液サンプルを得る工程;
b)このサンプルからDNAを抽出する工程;
c)複数のPCRプライマーを得る工程であって、これらプライマーの各々は、配列番号1、配列番号3、配列番号5、配列番号7、配列番号37、配列番号39、配列番号41、配列番号43、配列番号45、配列番号47または配列番号53由来の18〜1547連続するヌクレオチドからなる配列を含む、工程;
d)これらのプライマーを使用して、抽出されたDNAの領域を増幅してPCR産物を得る工程;
e)このPCR産物を分離する工程;ならびに
f)このPCR産物の配列と正常な遺伝子配列との間の違いを同定する工程、を包含し、
ここで、この増幅配列と正常な遺伝子配列との間の違いは、緑内障の診断特徴である。
a)BMP−2A、BMP4、BMP−5またはBMP7を発現する組換え細胞の集団を含む第一の組成物を得ること;
b)候補物質を得ること;
c)この組成物およびこの候補物質をインキュベートすること;
BMP誘導性Smadシグナル伝達経路および/またはBMP調節性の遺伝子発現を開始する能力について、この化合物を試験すること;ならびにBMPのこれらの下流の効果を阻害、または刺激する候補物質を同定すること。
小柱網は、房水の正常な流れにおいて、重要な役割を担うことが提案されており、そして緑内障の眼における流出抵抗の主な部位であると推測されている。ヒト小柱網(HTM)細胞は、房水が眼から出る流出チャネルを裏打ちする特殊化した細胞である。細胞の変化した合成機能は、POAG、ステロイド緑内障、および他のタイプの緑内障の病因に関与し得る。
(a)局所的な眼用処方 重量%
眼のBMP−4の発現を上昇させる薬剤 0.01〜2
HPMC 0.5
塩化ナトリウム 0.8
BAC 0.01
EDTA 0.01
NaOH/HCl qs pH7.4
精製水 qs 100mL
(b)局所的な眼用処方 重量%
グレムリンアンタゴニスト 0.01〜2
HPMC 0.5
塩化ナトリウム 0.8
BAC 0.01
EDTA 0.01
NaOH/HCl qs pH7.4
精製水 qs 100mL
(c)局所的な眼用処方 重量%
Smad1/5アゴニスト 0.01〜2
HPMC 0.5
塩化ナトリウム 0.8
BAC 0.01
EDTA 0.01
NaOH/HCl qs pH7.2
精製水 qs 100mL
本発明の化合物は、眼内挿入デバイス中で処方されることがさらに企図される。
本発明はまた、BMPシグナル伝達経路に関与する新しい抗緑内障治療剤の発見のために有用である(図5を参照のこと)。選択的BMPリガンドは、BMP I型およびBMP II型セリン/スレオニンキナーゼレセプター(BMP−RIおよびBMP−RII)に結合し、そしてSmadタンパク質を介してシグナルを伝達する。BMPシグナルは、タンパク質−タンパク質相互作用およびタンパク質−DNA相互作用を介して、Smadによって伝搬される(AttisanoおよびTuen Lee−Hoeflich 2001)。調節的Smad1およびSmad5は、BMPレセプターへのリガンドの結合によって(リン酸化を介して)活性化される(von BubnoffおよびCho 2001)。これらの調節的Smadは、その後、Smad4と相互作用して、核に転移するヘテロマー複合体を形成する。この複合体は、どの核補助因子が存在するかに依存して、この転写複合体を認識する選択的遺伝子の転写を活性化することまたは抑制することが可能である。
本発明は、緑内障の初期検出のための方法、化合物およびキットを提供する。このキットは、BMPポリペプチドまたはBMPタンパク質をコードする核酸セグメントを含み得る。このキットはさらに、サンプルと本発明の核酸またはペプチドとの間の相互作用を検出するための試薬を含み得る。提供された試薬は、放射性標識化、蛍光標識化、または酵素的標識化され得る。このキットは、本発明の核酸またはペプチドもしくはタンパク質と結合または相互作用し得る、公知の放射性標識された薬剤を含み得る。
細胞培養:ヒトTM細胞およびONH細胞を、ドナーの眼から記載されるように生成した(Steelyら、1992;Steelyら、2000;Wilsonら、1993;Clarkら、1994;Clarkら、1995b;Clarkら、1995c;Clarkら、1996;Clarkら、2001a;Clarkら、2001b;Dickersonら、1998;Wordingerら、1998;Wordingerら、1999;Wordingerら、2000;Wordingerら、2002;Lambertら、2001;Agarwalら、1999;Liuら、2001)。TM細胞を、年齢6日齢から90歳の範囲のドナーのTM外移植体から増殖させた。ヒト視神経乳頭星状細胞および篩板(LC)細胞を、慎重に解剖した視神経乳頭(2日齢〜90歳までの年齢のドナー)から生成し、そして以前の報告に従って特徴付けた(Lambertら、2001;Clarkら、1995a)。細胞を、以下の培地:TM細胞については10%ウシ胎仔血清(HyClone,Logan,UT)および抗生物質(Gibco BRL−Life Technologies,Grand Island,NY)を含むHam’s F10培地(JRH Biosciences、Lenexa、KS);LC細胞については10%FBSを含むダルベッコ改変イーグル培地(DMEM,HyClone);そしてONH星状細胞については5%FBSを含む星状細胞増殖培地(AGM,Clonetics,San Diego,CA)内で、コンフルエントまで増殖させた。
以下の参考文献は、例示的な手順、または本明細書中に記載される手順に対して補助的な他の詳細を提供する程度にまで、本明細書中で参考として具体的に援用される。
(書籍)
Claims (7)
- 細胞または体液から得られたサンプルにおいて、骨形態形成ファミリーメンバー遺伝子の発現の変化を検出することによる、緑内障を診断する方法であって、該方法は、以下の工程:
g)緑内障を有すると疑われる患者から組織または液体のサンプルを得る工程;
h)該サンプルからDNAを抽出する工程;
i)複数のPCRプライマーを得る工程であって、該プライマーの各々は、配列番号1、配列番号3、配列番号5、配列番号7、配列番号37、配列番号39、配列番号41、配列番号43、配列番号45、配列番号47または配列番号53由来の、18〜1547連続するヌクレオチドからなる配列を含む、工程;
j)該プライマーを使用して、該抽出されたDNAの領域を増幅してPCR産物を得る工程;
k)該PCR産物を分離する工程;ならびに
l)該増幅した抽出されたDNA配列と該プライマーの配列との間の違いを同定する工程、を包含し、
ここで該増幅配列とプライマーとの間の違いは、緑内障の診断特徴である、方法。 - 請求項1に記載の方法であって、前記組織サンプルまたは前記液体サンプルは、血液または頬の細胞である、方法。
- 請求項1に記載の方法であって、前記プライマーは、配列番号1、配列番号3、配列番号5、配列番号7、配列番号37、配列番号39、配列番号41、配列番号43、配列番号45、配列番号47または配列番号53の、20〜100連続するヌクレオチドからなる配列を包む、方法。
- 請求項1に記載の方法であって、前記プライマーは、配列番号3の20〜50連続するヌクレオチドからなる配列を包む、方法。
- 請求項1に記載の方法であって、前記PCR産物は、SSCP、DGGE,ASOまたはRFLPによって分離される、方法。
- 緑内障を処置する方法であって、該方法は、BMP2アゴニスト、BMP4アゴニスト、BMP5アゴニスト、BMP7アゴニスト、Smad1/5アゴニスト、コーディンアンタゴニスト、グレムリンアンタゴニストおよび、フォリスタチンアンタゴニストからなる群から選択される少なくとも1つの化合物からなる配列を包む組成物を、このような処置を必要とする患者に投与する工程を包含する、方法。
- 緑内障を処置するための治療剤を同定する方法であって、該方法は以下の工程:
d)BMP−2A、BMP4、BMP−5、またはBMP7を発現する組換え細胞の集団を含む、第一の組成物を得る工程;
e)候補物質を得る工程;
f)該組成物および該候補物質をインキュベートする工程;
g)該組成物を、BMP誘導性Smadシグナル伝達経路、またはBMP調節性の遺伝子発現を開始する能力について試験する工程;ならびに
h)BMP誘導性のSmadシグナル伝達経路、または該BMP調節性の遺伝子発現を阻害または刺激する候補物質を同定する工程、
を包含する、方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33485201P | 2001-10-31 | 2001-10-31 | |
PCT/US2002/035251 WO2003055443A2 (en) | 2001-10-31 | 2002-10-31 | Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008230352A Division JP2008301834A (ja) | 2001-10-31 | 2008-09-08 | 骨形成タンパク質(bmp)、bmpレセプターおよびbmp結合タンパク質ならびに緑内障の診断および処置におけるそれらの使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005518788A true JP2005518788A (ja) | 2005-06-30 |
JP4255382B2 JP4255382B2 (ja) | 2009-04-15 |
Family
ID=23309139
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003556021A Expired - Fee Related JP4255382B2 (ja) | 2001-10-31 | 2002-10-31 | 骨形成タンパク質(bmp)、bmpレセプターおよびbmp結合タンパク質ならびに緑内障の診断および処置におけるそれらの使用 |
JP2008230352A Pending JP2008301834A (ja) | 2001-10-31 | 2008-09-08 | 骨形成タンパク質(bmp)、bmpレセプターおよびbmp結合タンパク質ならびに緑内障の診断および処置におけるそれらの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008230352A Pending JP2008301834A (ja) | 2001-10-31 | 2008-09-08 | 骨形成タンパク質(bmp)、bmpレセプターおよびbmp結合タンパク質ならびに緑内障の診断および処置におけるそれらの使用 |
Country Status (16)
Country | Link |
---|---|
US (5) | US20050118585A1 (ja) |
EP (2) | EP2053135A1 (ja) |
JP (2) | JP4255382B2 (ja) |
KR (4) | KR20110032003A (ja) |
CN (2) | CN1685055A (ja) |
AT (1) | ATE349554T1 (ja) |
BR (1) | BR0213738A (ja) |
CA (1) | CA2463143A1 (ja) |
DE (1) | DE60217152T2 (ja) |
ES (1) | ES2278079T3 (ja) |
HK (1) | HK1069851A1 (ja) |
MX (1) | MXPA04003697A (ja) |
PL (2) | PL214839B1 (ja) |
RU (3) | RU2336902C2 (ja) |
WO (1) | WO2003055443A2 (ja) |
ZA (1) | ZA200402662B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010501188A (ja) * | 2006-08-24 | 2010-01-21 | アルコン リサーチ, リミテッド | IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害 |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04003697A (es) | 2001-10-31 | 2005-04-08 | Alcon Inc | Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma. |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
EP1627916B1 (en) | 2003-05-28 | 2009-11-25 | Takeda Pharmaceutical Company Limited | Anti-BAMBI antibodies or RNA for diagnosis and therapy of colon or liver cancer |
CA2475769C (en) * | 2003-08-28 | 2018-12-11 | Veridex, Llc | Colorectal cancer prognostics |
DK2489364T3 (en) | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
KR20070026650A (ko) | 2004-05-27 | 2007-03-08 | 악셀레론 파마 인코포레이티드 | 케르베루스/코코 유도체 및 그의 용도 |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
AU2006289667A1 (en) * | 2005-09-08 | 2007-03-15 | Apollo Life Sciences Limited | Noggin and chimeric molecules thereof |
RU2559532C2 (ru) | 2006-11-02 | 2015-08-10 | Акселерон Фарма, Инк. | Антагонисты рецептора и лигандов alk1 и их применение |
US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
CA2671983A1 (en) | 2006-12-08 | 2009-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
EP3398966A1 (en) | 2008-05-02 | 2018-11-07 | Acceleron Pharma, Inc. | Methods and compositions for modulating angiogenesis and pericyte composition |
RU2523419C2 (ru) | 2008-07-15 | 2014-07-20 | Дженетек, Инк. | Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений |
CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
ES2938049T3 (es) | 2009-10-16 | 2023-04-04 | Scripps Research Inst | Inducción de células pluripotentes |
WO2011116212A2 (en) * | 2010-03-17 | 2011-09-22 | Oncomed Pharmaceuticals, Inc. | Bone morphogenetic protein receptor binding agents and methods of their use |
EP2528625B1 (en) | 2010-04-15 | 2013-07-10 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CN103313990B (zh) | 2010-11-17 | 2016-07-20 | 基因泰克公司 | 丙氨酰美登醇抗体偶联物 |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
BR112014009050B1 (pt) | 2011-10-14 | 2022-06-21 | Medimmune Limited | Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
WO2013137686A1 (ko) * | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | 그렘린-1에 대한 항체 |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
NZ707490A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
NZ707534A (en) | 2012-10-12 | 2018-08-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
LT2839860T (lt) | 2012-10-12 | 2019-07-10 | Medimmune Limited | Pirolobenzodiazepinai ir jų konjugatai |
CA2887894C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
KR101995620B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
EA032986B1 (ru) | 2012-12-21 | 2019-08-30 | Медимьюн Лимитед | Пирролобензодиазепины |
AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
BR112015023333A8 (pt) | 2013-03-13 | 2018-04-17 | Medimmune Ltd | pirrolbenzodiazepinas e conjugados dos mesmos |
TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
EP2970448B1 (en) | 2013-03-14 | 2021-11-03 | Regeneron Pharmaceuticals, Inc. | Human antibodies to grem 1 |
KR20160042080A (ko) | 2013-08-12 | 2016-04-18 | 제넨테크, 인크. | 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법 |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
MX371092B (es) | 2013-12-16 | 2020-01-16 | Genentech Inc | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
BR112016013861A2 (pt) | 2013-12-16 | 2017-10-10 | Genentech Inc | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica |
EP3166624B1 (en) * | 2014-07-09 | 2020-06-03 | Mayo Foundation for Medical Education and Research | Treating rotator cuff conditions |
JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
TW201625688A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 經半胱胺酸改造之抗體及接合物 |
PE20170905A1 (es) | 2014-09-17 | 2017-07-12 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
EP3322481A4 (en) | 2015-07-16 | 2019-03-06 | Mayo Foundation for Medical Education and Research | TREATMENT OF ROTATOR COIL DRESSES |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
KR101921784B1 (ko) * | 2015-10-13 | 2018-11-23 | 사회복지법인 삼성생명공익재단 | 그램린-1을 코딩하는 뉴클레오타이드 또는 그램린-1을 유효성분으로 포함하는 안 질환 예방 또는 치료용 약제학적 조성물 |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN105807065B (zh) * | 2016-03-16 | 2018-10-02 | 沈慧勇 | BMP2和Noggin联合使用在制备强直性脊柱炎诊断试剂盒中的应用 |
CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
CN106086229B (zh) * | 2016-08-26 | 2019-08-16 | 广东省农业科学院动物科学研究所 | 鸡生长性状相关的分子标记及其鉴别方法和应用 |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
PT3544636T (pt) | 2017-02-08 | 2021-05-04 | Medimmune Ltd | Conjugados de anticorpos-pirrolobenzodiazepinas |
HUE059828T2 (hu) | 2017-04-18 | 2023-01-28 | Medimmune Ltd | Pirrolobenzodiazepin konjugátumok |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
SI3668874T1 (sl) | 2017-08-18 | 2022-04-29 | Medimmune Limited | Pirolobenzodiazepinski konjugati |
KR20220156974A (ko) | 2017-09-20 | 2022-11-28 | 주식회사 피에이치파마 | 타일란스타틴 유사체 |
CN108531608B (zh) * | 2018-01-24 | 2020-06-30 | 华南农业大学 | Bmp6基因作为黑山羊产羔数性状的分子标记 |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
WO2024138128A2 (en) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001945A1 (en) * | 1987-08-28 | 1989-03-09 | The Salk Institute For Biological Studies | Follistatin and method of purifying same |
WO1992021365A1 (en) * | 1991-06-05 | 1992-12-10 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
WO1995030003A2 (en) * | 1994-04-29 | 1995-11-09 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
WO1996040771A1 (en) * | 1995-06-07 | 1996-12-19 | Creative Biomolecules, Inc. | SINGLE CHAIN ANALOGS OF THE TGF-β SUPERFAMILY (MORPHONS) |
WO1998021335A1 (en) * | 1996-11-14 | 1998-05-22 | Genetics Institute, Inc. | Chordin compositions |
WO2000050637A1 (en) * | 1999-02-26 | 2000-08-31 | Hibergen Limited | Identification of genes having a role in the presentation of diabetic nephropathy |
WO2000061774A2 (en) * | 1999-04-09 | 2000-10-19 | Human Genome Sciences, Inc. | Bone morphogenic proteins |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1224795B (it) * | 1988-12-01 | 1990-10-24 | Sigma Tau Ind Farmaceuti | Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento |
US5364884A (en) * | 1993-01-21 | 1994-11-15 | Baylor College Of Medicine | Arginine compounds as ocular hypotensive agents |
US5606043A (en) | 1994-11-03 | 1997-02-25 | The Regents Of The University Of California | Methods for the diagnosis of glaucoma |
US5856094A (en) * | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
ES2152563T3 (es) * | 1995-08-31 | 2001-02-01 | Lonza Ag | Procedimiento para preparar derivados de dihidroxipirimidina. |
WO1998020131A1 (en) * | 1996-11-08 | 1998-05-14 | University Of Iowa Research Foundation | Glaucoma-associated protein and corresponding nucleic acid and their therapeutic and diagnostic uses |
WO1998020889A1 (en) * | 1996-11-15 | 1998-05-22 | Creative Biomolecules Inc | Morphogen peptide-induced regeneration of sense perceptory tissues |
EP0943014B1 (en) * | 1996-12-05 | 2007-02-21 | Alcon Manufacturing, Ltd. | Methods for diagnosing glaucoma and discovering anti-glaucoma drugs |
US5989885A (en) * | 1997-01-10 | 1999-11-23 | Myriad Genetics, Inc. | Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer |
JP2001515493A (ja) * | 1997-03-14 | 2001-09-18 | セレクティブ ジェネティックス,インコーポレイテッド | 改変された親和性を有するアデノウイルスベクター |
US6207450B1 (en) * | 1998-04-15 | 2001-03-27 | University Of Iowa Research Foundation | Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
EP1179052A4 (en) * | 1999-05-07 | 2004-12-15 | Human Genome Sciences Inc | SERINE PROTEASES |
AU5457000A (en) * | 1999-06-11 | 2001-01-02 | Human Genome Sciences, Inc. | 48 human secreted proteins |
WO2002077006A1 (en) * | 2001-03-23 | 2002-10-03 | Human Genome Sciences, Inc. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
WO2002085909A1 (en) | 2001-04-20 | 2002-10-31 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
MXPA04003697A (es) * | 2001-10-31 | 2005-04-08 | Alcon Inc | Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma. |
KR20070058445A (ko) | 2004-07-02 | 2007-06-08 | 스트라스바흐, 인코포레이티드 | 웨이퍼 처리 방법 및 시스템 |
-
2002
- 2002-10-31 MX MXPA04003697A patent/MXPA04003697A/es active IP Right Grant
- 2002-10-31 PL PL396553A patent/PL214839B1/pl unknown
- 2002-10-31 US US10/492,380 patent/US20050118585A1/en not_active Abandoned
- 2002-10-31 KR KR1020117005285A patent/KR20110032003A/ko not_active Application Discontinuation
- 2002-10-31 CN CNA028209176A patent/CN1685055A/zh active Pending
- 2002-10-31 ES ES02802562T patent/ES2278079T3/es not_active Expired - Lifetime
- 2002-10-31 CN CNA2006101467420A patent/CN1966725A/zh active Pending
- 2002-10-31 BR BRPI0213738-0A patent/BR0213738A/pt not_active Application Discontinuation
- 2002-10-31 EP EP08019507A patent/EP2053135A1/en not_active Withdrawn
- 2002-10-31 WO PCT/US2002/035251 patent/WO2003055443A2/en active Application Filing
- 2002-10-31 EP EP02802562A patent/EP1440159B1/en not_active Expired - Lifetime
- 2002-10-31 AT AT02802562T patent/ATE349554T1/de not_active IP Right Cessation
- 2002-10-31 US US10/286,152 patent/US7405192B2/en not_active Expired - Fee Related
- 2002-10-31 KR KR1020047005671A patent/KR100996226B1/ko not_active IP Right Cessation
- 2002-10-31 CA CA002463143A patent/CA2463143A1/en not_active Withdrawn
- 2002-10-31 PL PL02373863A patent/PL373863A1/xx not_active Application Discontinuation
- 2002-10-31 RU RU2004116308/15A patent/RU2336902C2/ru not_active IP Right Cessation
- 2002-10-31 DE DE60217152T patent/DE60217152T2/de not_active Expired - Lifetime
- 2002-10-31 JP JP2003556021A patent/JP4255382B2/ja not_active Expired - Fee Related
- 2002-10-31 KR KR1020107001960A patent/KR20100013352A/ko active Application Filing
- 2002-10-31 KR KR1020107026384A patent/KR101072867B1/ko not_active IP Right Cessation
-
2004
- 2004-04-05 ZA ZA200402662A patent/ZA200402662B/en unknown
- 2004-12-16 HK HK04110026A patent/HK1069851A1/xx not_active IP Right Cessation
-
2008
- 2008-04-21 US US12/106,653 patent/US7744873B2/en not_active Expired - Fee Related
- 2008-06-03 RU RU2008122296/15A patent/RU2008122296A/ru not_active Application Discontinuation
- 2008-09-08 JP JP2008230352A patent/JP2008301834A/ja active Pending
-
2010
- 2010-04-23 US US12/766,056 patent/US8063013B2/en not_active Expired - Fee Related
-
2011
- 2011-10-26 US US13/281,816 patent/US8389496B2/en not_active Expired - Fee Related
-
2012
- 2012-05-16 RU RU2012120343/15A patent/RU2012120343A/ru not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001945A1 (en) * | 1987-08-28 | 1989-03-09 | The Salk Institute For Biological Studies | Follistatin and method of purifying same |
WO1992021365A1 (en) * | 1991-06-05 | 1992-12-10 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
WO1995030003A2 (en) * | 1994-04-29 | 1995-11-09 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
WO1996040771A1 (en) * | 1995-06-07 | 1996-12-19 | Creative Biomolecules, Inc. | SINGLE CHAIN ANALOGS OF THE TGF-β SUPERFAMILY (MORPHONS) |
WO1998021335A1 (en) * | 1996-11-14 | 1998-05-22 | Genetics Institute, Inc. | Chordin compositions |
WO2000050637A1 (en) * | 1999-02-26 | 2000-08-31 | Hibergen Limited | Identification of genes having a role in the presentation of diabetic nephropathy |
WO2000061774A2 (en) * | 1999-04-09 | 2000-10-19 | Human Genome Sciences, Inc. | Bone morphogenic proteins |
Non-Patent Citations (5)
Title |
---|
BONE, vol. 19, no. 6, JPN6008028060, 1996, pages 569 - 574, ISSN: 0001231112 * |
EXP. EYE RES., vol. 70, JPN6008028057, 2000, pages 17 - 30, ISSN: 0001231111 * |
IOVS, vol. 40, no. 2, JPN6008028051, 1999, pages 296 - 311, ISSN: 0001060413 * |
IOVS, vol. 41, no. 12, JPN6008028054, 2000, pages 3833 - 3841, ISSN: 0001231110 * |
SCIENCE, vol. 275, JPN6008028061, 1997, pages 668 - 670, ISSN: 0001231113 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010501188A (ja) * | 2006-08-24 | 2010-01-21 | アルコン リサーチ, リミテッド | IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4255382B2 (ja) | 骨形成タンパク質(bmp)、bmpレセプターおよびbmp結合タンパク質ならびに緑内障の診断および処置におけるそれらの使用 | |
US20070141609A1 (en) | Screening and Therapy for Lymphatic Disorders Involving the FLT4 Receptor Tyrosine Kinase (VEGFR-3) | |
US7829536B2 (en) | Method of treating lymphedema comprising administering VEGF-D | |
AU2020202676B2 (en) | Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5 | |
JP2012025763A (ja) | 緑内障の診断及び治療方法 | |
JP2022523301A (ja) | アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療 | |
KR20190095074A (ko) | 뇌 종양 동물 모델 및 이의 제조 방법 | |
WO2006095559A1 (ja) | 造血因子としてのFgf21の使用 | |
JP2009511057A (ja) | 黄斑変性に関与する遺伝子 | |
CA2759457C (en) | Association of htra1 mutations and familial ischemic cerebral small-vessel disease | |
US20200172974A1 (en) | Biomarker for anti-tnf therapy in retinal diseases | |
AU2002364946B2 (en) | Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma | |
EP1738767A1 (en) | Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma | |
RU2812912C2 (ru) | Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7) | |
Wu et al. | Genetic alterations of HOXA10 and their effect on the severity of endometriosis in a Taiwanese population |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090121 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090127 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120206 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |